Form 4: Longeveron CFO Lisa Locklear Awarded Significant Equity Grants

Longeveron Inc.'s Chief Financial Officer, Lisa Locklear, was granted 102,000 Restricted Stock Units and 34,000 stock options, aligning her interests with long-term company performance.

Summary

• Lisa Locklear, Chief Financial Officer of Longeveron Inc. (LGVN), was awarded 102,000 time-based vesting Restricted Stock Units (RSUs) on July 15, 2025.
• The RSUs were acquired at a price of $0, reflecting their nature as equity compensation.
• Following this transaction, Lisa Locklear beneficially owns 239,198 Class A Common Stock, which includes RSUs subject to future vesting.
• Additionally, Locklear was granted 34,000 stock options on July 15, 2025, with an exercise price of $1.47 per share.
• These stock options have an expiration date of July 15, 2035.
• The stock options will vest quarterly over a three-year period, commencing on October 1, 2025.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to a key executive like the CFO is generally a positive signal, indicating management's long-term commitment and confidence in the company's future, and aligning their interests with shareholders.

Positives

• The award of 102,000 Restricted Stock Units (RSUs) and 34,000 stock options to the Chief Financial Officer indicates a strong commitment to retaining key management and aligning their interests with shareholder value.
• Equity grants at a $0 price for RSUs and a specified exercise price for options are standard compensation practices, signaling confidence in the company's future performance.
• The vesting schedule for both RSUs and stock options encourages long-term focus and performance from the CFO.

Future Outlook

The equity grants, particularly the stock options vesting quarterly over three years starting October 1, 2025, indicate a long-term outlook for the company's performance and a strategy to retain key executive talent through future-vesting compensation.

Management Comments

• The filing was signed by Paul Lehr, attorney-in-fact for Lisa Locklear.

Industry Context

This Form 4 filing reflects a standard practice of executive compensation within the biotechnology or life sciences industry, where equity grants are commonly used to incentivize and retain key personnel, aligning their financial interests with the long-term success and growth of the company.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) and stock options to a Chief Financial Officer is a common compensation structure in publicly traded companies, particularly in growth-oriented sectors like biotechnology, comparable to practices at companies such as Moderna, BioNTech, or Regeneron Pharmaceuticals, where executive compensation often includes significant equity components to align management incentives with shareholder returns.
• The vesting schedule of quarterly over three years for stock options is a typical industry standard designed to encourage long-term retention and performance.

Related Party Transactions

• The transaction involves the award of equity compensation to a corporate officer, which is a common form of related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The equity grants align the CFO's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: May signal stability and confidence in the company's future, potentially boosting morale.
• Management: Provides significant long-term incentives and retention for a key executive.

Next Steps

• The granted stock options will begin vesting quarterly over a three-year period starting October 1, 2025.
• The Restricted Stock Units (RSUs) are subject to future time-based vesting.

Key Dates

Recommendation

Keywords

Longeveron Inc., LGVN, Lisa Locklear, Chief Financial Officer, CFO, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Insider Transaction, SEC Form 4, Corporate Governance, Executive Compensation